Actively Recruiting
Observational Study Evaluating Aflibercept 8 mg Treatment in Adults Aged 50 and Older with Neovascular Age-Related Macular Degeneration
Led by Peking University People's Hospital · Updated on 2026-06-11
300
Participants Needed
27
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study explores the use of aflibercept 8 mg in adults aged 50 and older with neovascular age-related macular degeneration nAMD. It evaluates the treatments short-term and long-term effects on patients who are either new to treatment or previously treated. The study aims to understand the safety, treatment patterns, and effectiveness of aflibercept 8 mg in real-world clinical practice. Participants receive aflibercept 8 mg as part of their routine clinical care without additional study interventions. Two groups include treatment-naive and previously treated nAMD patients, each observed for up to 12 months from the start of aflibercept 8 mg therapy. The observation ends if patients switch treatments, withdraw consent, become pregnant, pass away, or are lost to follow-up. During the study, participants undergo regular assessments including measurements of best corrected visual acuity BCVA and central subfield thickness CST at multiple intervals up to 12 months. Researchers also monitor adverse events, treatment regimens, injection counts, and visual and anatomical changes. This data will help inform clinical decisions and improve understanding of aflibercept 8 mg in everyday medical settings.
CONDITIONS
Brief Title
Real-world Study of Aflibercept 8 mg in nAMD
Research Team
M
Mingwei Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here